CPA
AKRO

Capital Performance Advisors’s Akero Therapeutics AKRO Stock Holding History

Capital Performance Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$574 – 253
2024
Q3 		$574 Buy
+20
New +$521 ﹤0.01% 2185

Other funds holding AKRO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Capital Performance Advisors's AKRO Position: Q4 2024 in Review

Capital Performance Advisors sold out of Akero Therapeutics (AKRO) in Q4 2024, closing a stake of 20 shares — an estimated $574 sold.

Capital Performance Advisors first reported a position in AKRO in Q3 2024 and held it in 1 quarter. The position peaked at $574 in Q3 2024. 191 funds tracked by Wall St. Rank hold AKRO as of Q4 2024.

  • Capital Performance Advisors reported no remaining Akero Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 20 Akero Therapeutics shares in Q4 2024, an estimated $574.
  • Capital Performance Advisors first reported a position in Akero Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Akero Therapeutics position peaked at $574 in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.